Abstract
Background We investigated the effect of HIV on COVID-19 outcomes with attention to selection bias due to differential testing and to comorbidity burden.
Methods Retrospective cohort analysis using four hierarchical outcomes: positive SARS-CoV-2 test, COVID-19 hospitalization, intensive care unit (ICU) admission, and hospital mortality. The effect of HIV status was assessed using traditional covariate-adjusted, inverse probability weighted (IPW) analysis based on covariate distributions for testing bias (testing IPWs), HIV infection status (HIV IPWs), and combined models. Among PWH, we evaluated whether CD4 count and HIV plasma viral load (pVL) discriminated between those who did or did not develop study outcomes using receiver operating characteristic analysis.
Results Between March and November 2020, 63,319 people were receiving primary care services at UCSD, of whom 4,017 were people living with HIV (PWH). PWH had 2.1 times the odds of a positive SARS-CoV-2 test compared to those without HIV after weighting for potential testing bias, comorbidity burden, and HIV-IPW (95% CI 1.6-2.8). Relative to persons without HIV, PWH did not have an increased rate of COVID-19 hospitalization after controlling for comorbidities and testing bias [adjusted incidence rate ratio (aIRR): 0.5, 95% CI: 0.1 – 1.4]. PWH had neither a different rate of ICU admission (aIRR:1.08, 95% CI; 0.31 – 3.80) nor in-hospital death (aIRR:0.92, 95% CI; 0.08 – 10.94) in any examined model. Neither CD4 count nor pVL predicted any of the hierarchical outcomes among PWH.
Conclusions PWH have a higher risk of COVID-19 diagnosis but similar outcomes compared to those without HIV.
Summary point After considering the effects of potential bias due to differential testing, comorbidities, and other patient characteristics, people with HIV had an increased rate of SARS-CoV-2 positivity and similar rates of hospitalization, ICU admission, and death.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: ERC receives unrestricted research funds from Gilead Sciences and Merck Sharp & Dohme for unrelated research, which are paid to UC Regents, ERC participates in the medical advisory board for Gilead Sciences; no other relationships or activities that could appear to have influenced the submitted work
Funding Statement
This work was supported in part by the Office of the President of the University of California COVID-19 seed grant and The University of California San Diego Center for AIDS Research [AI036214]. MET and TG were supported by funding from the National Institute of Health (NIH) Grants T32AI007384-29, T32AI007036-39. The project described was partially supported by the NIH, Grant 2UL1TR001442-06 of CTSA funding. The funders had no role in study design, decision to publish, or preparation of the manuscript. The opinions expressed in this paper are those of the authors and do not necessarily represent those of the funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of California San Diego gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported in part by the Office of the President of the University of California COVID-19 seed grant and The University of California San Diego Center for AIDS Research [AI036214]. ME Tang and T Gaufin are supported by funding from the National Institute of Health (NIH) Grant T32AI007384-29, T32AI007036-39. The project described was partially supported by the NIH, Grant 2UL1TR001442-06 of CTSA funding. The funders had no role in study design, decision to publish, or preparation of the manuscript. The opinions expressed in this paper are those of the authors and do not necessarily represent those of the funders.
Disclosures: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: ERC receives unrestricted research funds from Gilead Sciences and Merck Sharp & Dohme for unrelated research, which are paid to UC Regents, ERC also participates in the medical advisory board for Gilead Sciences; no other relationships or activities that could appear to have influenced the submitted work
Data Availability
All data produced in the present study are available upon reasonable request to the authors
